JSPR (Jasper Therapeutics) 5-Year EBITDA Growth Rate: 19.10% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JSPR Jasper Therapeutics Inc JSPR
30 GF Score
Price $0.71
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics 5-Year EBITDA Growth Rate?

Jasper Therapeutics JSPR +0.79% 30 5-Year EBITDA Growth Rate is 19.10% as of Jun. 2026. GuruFocus rates JSPR with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Jasper Therapeutics's EBITDA per Share for the three months ended in Jun. 2026 was $-0.32.

During the past 3 years, the average EBITDA Per Share Growth Rate was 32.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Jasper Therapeutics was 45.70% per year. The lowest was -5.90% per year. And the median was 32.00% per year.

Jasper Therapeutics  (NAS:JSPR) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Jasper Therapeutics 5-Year EBITDA Growth Rate Related Terms

JSPR vs CNSY, MRKR, ENLV: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Jasper Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jasper Therapeutics 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's 5-Year EBITDA Growth Rate falls into.


JSPR
30GF Score
Jasper Therapeutics Inc JSPR
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 19.10% mean?
Jasper Therapeutics (JSPR) has a 5-Year EBITDA Growth Rate of 19.10% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Jasper Therapeutics and its competitors.
Is Jasper Therapeutics' 5-Year EBITDA Growth Rate too high?
Jasper Therapeutics' current 5-Year EBITDA Growth Rate is 19.10%. Overall, Jasper Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' 5-Year EBITDA Growth Rate compare to CNSY and MRKR?
Jasper Therapeutics' 5-Year EBITDA Growth Rate of 19.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Jasper Therapeutics and its competitors. Jasper Therapeutics's current 5-Year EBITDA Growth Rate is 19.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current 5-Year EBITDA Growth Rate of 19.10%. The current 5-Year EBITDA Growth Rate is 19.10%. Jasper Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current 5-Year EBITDA Growth Rate is 19.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
30GF Score

Get the complete analysis for JSPR

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price